Can we quantify the quality of vision?

Article

The age of refractive surgery has introduced new aberrations to the human eye that require a shift in how visual performance is evaluated, said Ray Applegate, MD. Mesopic low contrast acuity best quantifies vision quality; it overcomes the weaknesses of other metrics and it can predict visual function among individuals.

The age of refractive surgery has introduced new aberrations to the human eye that require a shift in how visual performance is evaluated, said Ray Applegate, MD. Mesopic low contrast acuity best quantifies vision quality; it overcomes the weaknesses of other metrics and it can predict visual function among individuals.

Dr Applegate recruited 168 people with 6/6 or better vision across a range of ages and conducted a photopic high-contrast logMAR acuity test. "The test could only account for around 4% of the variation in our sample," he said. "We can't use it to predict the visual function of individuals. However mesopic low-contrast logMAR acuity accounted for a much broader range of the variation."

Dr Applegate said high contrast acuity is a poor metric because it is conducted under high luminance conditions and has excess contrast allowing a loss in contrast and image fidelity without a loss in measured acuity.

Contrast sensitivity, on the other hand, is impractical because it requires measurements along many different orientations. "That is simply not practical in the clinical environment and it is totally insensitive to phase shifts," insisted Applegate.

But mesopic low contrast acuity allows a large physiologic pupil and is sensitive to phase shifts and contrast loss. "It's also a recognition task as opposed to a detection task that's understood by clinicians and patients and it's easy to administer in a clinical setting," he said.

The study will be published shortly in Optometry and Vision Science.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.